Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
12%
Bevacizumab
26%
Blood Samples
10%
Blood-based
16%
Cancer Database
11%
Cancer Patients
11%
Carbohydrate Antigen 125 (CA125)
16%
Carbohydrate Antigen 19-9 (CA19-9)
11%
Carcinoembryonic Antigen
16%
Chemotherapy
15%
Colonoscopy
18%
Colorectal Cancer
100%
Colorectal Cancer Patients
15%
Comorbidity
13%
Confidence Interval
25%
Denmark
11%
Early Detection
22%
Endoscopy
15%
Epithelial Ovarian Cancer
25%
Glioblastoma
12%
Hazard Ratio
23%
Immunohistochemistry
13%
Interleukin-6
14%
Irinotecan
16%
Melanoma
12%
Metastatic Colorectal Cancer (mCRC)
23%
Multivariate Analysis
14%
National Cohort Study
13%
Ovarian Cancer
45%
Ovarian Cancer Patients
27%
Overall Survival
48%
Patients with Colorectal Cancer
15%
Plasma Tissue
17%
Poor Prognosis
13%
Predictive Value
14%
Prognostic Factors
22%
Prognostic Impact
12%
Prognostic Marker
16%
Prognostic Value
36%
Progression-free Survival
17%
Protein Biomarkers
11%
Radical Prostatectomy
15%
Recurrent Glioblastoma
15%
Risk Factors
12%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
54%
Tissue Inhibitor of metalloproteinase-1 (TIMP-1)
62%
Tumor
16%
Tumor Tissue
15%
Urokinase-type Plasminogen Activator
11%
YKL-40
38%
Medicine and Dentistry
Adenoma
7%
Bevacizumab
7%
Biological Marker
55%
Biopsy
11%
Breast Cancer
10%
CA-125
16%
Cancer
10%
Cancer Cell
9%
Clinical Stage
8%
Cohort Analysis
10%
Colonoscopy
14%
Colorectal Cancer
51%
Colorectal Liver Metastasis
8%
Diagnosis
17%
Disease
15%
Endoscopy
7%
Female Genital Tract Cancer
8%
Ganglioglioma
7%
Germ Cell Cancer
7%
Glioblastoma
12%
Hazard Ratio
21%
Human Epididymis Protein 4
7%
Immunohistochemistry
10%
Irinotecan
8%
Krukenberg Tumor
29%
Malignant Neoplasm
31%
Metastatic Carcinoma
8%
Metastatic Colorectal Cancer
8%
microRNA
10%
Multivariate Analysis
12%
Neoplasm
51%
Nodular Melanoma
13%
Ovarian Cancer
50%
Overall Survival
36%
Pelvis
11%
Positron Emission Tomography-Computed Tomography
8%
Primary Tumor
8%
Prognostic Factor
22%
Progression Free Survival
15%
Proportional Hazards Model
10%
Prostate Cancer
22%
Prostatectomy
10%
Protein Expression
12%
Rectum Cancer
7%
Seminoma
7%
Tissue Inhibitor of Metalloproteinase 1
15%
Triage
9%
Urokinase
7%
Urokinase Receptor
23%
Venous Ulcer
8%
